Menkes

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, March 28, 2024
AstraZeneca, Exercise, Fortification, New Drug Application, Patient, GBM, CRL, NDA, Menkes, Minocycline, Therapy, Marketing, Radiation, CKPT, Rosacea, Investigational New Drug, Erythema, Safety, BLA, Fortress Biotech, Food, Red, Amyloidosis, Dermatology, Carcinoma, FDA, Hyperhidrosis, Mustang Bio, Menkes disease, PDUFA, Pharmaceutical industry

MIAMI, March 28, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced financial results and recent corporate highlights for the full-year ended December 31, 2023.

Key Points: 
  • Lindsay A. Rosenwald, M.D., Fortress’ Chairman, President and Chief Executive Officer, said, “In 2023, we built a significant amount of momentum to position our Company to achieve multiple milestones in 2024.
  • In March 2024, the FDA accepted the NDA and has set a PDUFA goal date of November 4, 2024.
  • In December 2023, the FDA issued a complete response letter (“CRL”) for the cosibelimab BLA.
  • Fortress’ consolidated net revenue totaled $84.5 million for the full year ended December 31, 2023, which included $59.7 million in net revenue generated from our marketed dermatology products.

Sentynl Therapeutics Completes Asset Transfer of CUTX-101 Copper Histidinate Product Candidate for Treatment of Menkes Disease from Cyprium Therapeutics

Retrieved on: 
Wednesday, December 6, 2023
NDA, Fortress Biotech, Safety, Hope, Therapy, Assumption, Disease, Patient, U.S. FDA, FDA, Menkes disease, Caregiver, New Drug Application, Fortification, Death, Parent, Pharmaceutical industry, Menkes, Cyprium

SOLANA BEACH, Calif. and AHMEDABAD, India, Dec. 6, 2023 /PRNewswire/ -- Sentynl Therapeutics, Inc. (Sentynl), a U.S.-based biopharmaceutical company wholly-owned by Zydus Lifesciences, Ltd. (Zydus Group), today announced the execution of an Assignment and Assumption Agreement with Cyprium Therapeutics, Inc. (Cyprium), a Fortress Biotech, Inc. (Nasdaq: FBIO) (Fortress) subsidiary company. Under the agreement, Cyprium completed the transfer of its worldwide proprietary rights and U.S. FDA documents pertaining to CUTX-101, the copper histidinate product candidate for the treatment of Menkes disease, to Sentynl.

Key Points: 
  • Under the agreement, Cyprium completed the transfer of its worldwide proprietary rights and U.S. FDA documents pertaining to CUTX-101, the copper histidinate product candidate for the treatment of Menkes disease, to Sentynl.
  • Sentynl now assumes full responsibility for the development and commercialization of CUTX-101.
  • In 2021, Sentynl and Cyprium reported positive results from a safety and efficacy analysis of data integrated from two completed pivotal studies in patients with Menkes disease treated with CUTX-101.
  • This novel, breakthrough therapy could unlock possibilities for the treatment of the life threatening Menkes disease."

ATTEN…TION! Canadian Armed Forces and Royal Canadian Navy return to Toronto Waterfront Festival

Retrieved on: 
Wednesday, July 12, 2023
102nd Grey Cup, Menkes, Partnership, LAV, Life, Royal Canadian Navy, Textron Tactical Armoured Patrol Vehicle, Murray Menkes, Military, Queen's Quay Terminal, Central Band of the Canadian Armed Forces, Porter Airlines, TAPV, Commander, Waterfront, Westin Harbour Castle Hotel, SONAR, HMCS Oriole, Redpath Sugar, Toronto Regional Real Estate Board, Billy Bishop Toronto City Airport, Social media, Fireworks, Entertainment

TORONTO, July 12, 2023 (GLOBE NEWSWIRE) -- The Toronto Waterfront Festival, formerly Redpath Waterfront Festival, is excited to announce the return of the Canadian Armed Forces and Royal Canadian Navy to the 2023 festival.

Key Points: 
  • TORONTO, July 12, 2023 (GLOBE NEWSWIRE) -- The Toronto Waterfront Festival, formerly Redpath Waterfront Festival, is excited to announce the return of the Canadian Armed Forces and Royal Canadian Navy to the 2023 festival.
  • The festival, which is in partnership with the Waterfront BIA, will also welcome back the Royal Canadian Navy with on-land and on-water activations including the HMCS Oriole sail training vessel, which is celebrating its 102nd anniversary.
  • The Royal Canadian Navy will also have their mascot SONAR and equipment on-land for people to explore and interact with.
  • “The Canadian Armed Forces is proud to participate in events across Canada, and we welcome all Canadians to come out to meet our personnel and see our equipment,” stated Colonel Nickolas Roby, Commander, Canadian Armed Forces Recruiting Group.

The Friends of A.L.I.C.E. Scholarship Fund to Provide Education Assistance

Retrieved on: 
Friday, February 10, 2023
Education, Community foundation, Organization, Communication, Life, Friends, Marketing, Menkes, Student, Face, Hospital

FREDERICK, Md., Feb. 10, 2023 /PRNewswire-PRWeb/ -- The Friends of A.L.I.C.E. Scholarship Fund has been established with The Community Foundation of Frederick County and becomes one of its more than 770 component charitable funds.

Key Points: 
  • FREDERICK, Md., Feb. 10, 2023 /PRNewswire-PRWeb/ -- The Friends of A.L.I.C.E.
  • Scholarship Fund has been established with The Community Foundation of Frederick County and becomes one of its more than 770 component charitable funds.
  • Scholarship Fund to directly impact non-traditional learners pursuing a 4-year degree that face some financial hardship.
  • The Community Foundation works with individuals, families, businesses, and organizations to establish charitable funds that provide grants to area nonprofits and scholarships to students.

The Shack is Back for its Sweetest Event yet

Retrieved on: 
Saturday, December 17, 2022
Waterfront, Menkes, Redpath Sugar, Mountain Empire Community College, Sugar shack, Sugar Shack, Tourism, Billy Bishop Airport, Snow, COVID-19, Menkes Developments, Maple syrup, Canadiana

On March 11 and 12, 2023, this annual outdoor event will transform Sugar Beach into a Canadiana extravaganza featuring all things maple.

Key Points: 
  • On March 11 and 12, 2023, this annual outdoor event will transform Sugar Beach into a Canadiana extravaganza featuring all things maple.
  • In 2020, two days before Sugar Shack TO was supposed to happen, COVID-19 was declared a global pandemic which resulted in the cancellation of all festivals and events.
  • “We are more than excited to bring Sugar Shack TO back to Toronto’s waterfront for a safe outdoor event,” said Victoria Mahoney, co-producer.
  • Water’s Edge Festivals & Events is an Ontario not-for-profit corporation created in 2011 with a mandate to increase tourism to Toronto’s waterfront.

Sentynl Therapeutics Recognizes Menkes Disease Awareness Month, Committed to the Development of Tests for Early Diagnosis of Patients with Menkes Disease

Retrieved on: 
Tuesday, November 8, 2022
Diagnosis, Genetic distance, Infant, Institute, Patient, FDA, Compliance, SAN, Rady Children's Hospital, Mortality, Projection screen, Molecular genetics, Texas Institute for Genomic Medicine, Awareness, ATP7A, Metabolism, Menkes disease, Founder, Hypotonia, Genetic testing, Degenerative disease, Whole genome sequencing, Seizure, Therapy, Hair, Male, Failure, Pharmaceutical industry, Occipital horn syndrome, Menkes

Sentynl Therapeutics Recognizes Menkes Disease Awareness Month, Supports Development of Tests For Early Diagnosis

Key Points: 
  • Sentynl Therapeutics Recognizes Menkes Disease Awareness Month, Supports Development of Tests For Early Diagnosis
    Today, most patients with Menkes disease are misdiagnosed or diagnosed late after irreversible neurodevelopmental damage has occurred.
  • Over the last year, Sentynl has been advocating for the inclusion of the ATP7A gene in commercially-available genetic panels.
  • We are thrilled to partner with Sentynl Therapeutics in promoting awareness of Menkes disease."
  • Menkes disease is a rare X-linked recessive pediatric disease caused by gene mutations of the copper transporter ATP7A.

EQS-News: Fortress Bio’s Portfolio Of Marketed Drugs Could Soon See Three Additions

Retrieved on: 
Thursday, October 6, 2022
AstraZeneca, Fortification, Therapy, Rheumatoid arthritis, Life, Hospital, Neoplasm, Nationwide Children's Hospital, Dermatology, NDA, Food and Drug Administration Amendments Act of 2007, American College of Medical Genetics and Genomics, Minocycline, NASDAQ, Patient, Drug development, Cell, Checkpoint, Extrapyramidal system, Kidney, ACMG, Cancer, Degenerative disease, GI, Food, Immune system, Menkes disease, CKPT, Rosacea, Fortress Biotech, Gastrointestinal tract, Medical genetics, Immunotherapy, Copper, Liver, Advertising, Injection, Survival, Radiation, St. Jude Children's Research Hospital, Brain, Clinical trial, Doxycycline, CSCC, City, Death, American College, Acne, PD-L1, FDA, City of Hope, Skin cancer, Fred Hutchinson Cancer Research Center, Fine chemical, Pharmaceutical industry, Vaccine, Menkes, Cyprium, Genomics

Fortress Biotech Inc. (NASDAQ: FBIO) is a biopharmaceutical company focused on developing a range of high-potential treatments on its own and through its growing portfolio of subsidiaries and partner companies.

Key Points: 
  • Fortress Biotech Inc. (NASDAQ: FBIO) is a biopharmaceutical company focused on developing a range of high-potential treatments on its own and through its growing portfolio of subsidiaries and partner companies.
  • The novel cancer immunotherapy is being studied as a possible treatment for advanced cutaneous squamous cell carcinoma (cSCC), a difficult-to-treat skin cancer.
  • The current first-line treatment for cSCC is surgery to remove the tumor or radiation therapy to destroy the tumor.
  • Fortress Biotech, Inc. ("Fortress") is an innovative biopharmaceutical company focused on acquiring, developing and commercializing high-potential marketed and development-stage drugs and drug candidates.

Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented at 2021 American Academy of Pediatrics National Conference & Exhibition

Retrieved on: 
Thursday, October 14, 2021
Menkes, Death, Fortification, Nasdaq, ATP7A, NDA, Poster, Fortress Biotech, Conference, FDA, Premature, Patient, American Academy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, OS, Exhibition, Therapy, Menkes disease, Pharmaceutical industry

These data will be presented as a virtual poster at the 2021 American Academy of Pediatrics National Conference & Exhibition.

Key Points: 
  • These data will be presented as a virtual poster at the 2021 American Academy of Pediatrics National Conference & Exhibition.
  • These positive data demonstrate the potential of CUTX-101 to be an effective therapy for patients with this devastating disease.
  • The primary efficacy endpoint comparing CuHis-ET to HC-ET and the secondary efficacy endpoint comparing CuHis-LT to HC-LT were both met.
  • Cyprium Therapeutics, Inc. ("Cyprium") is focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders.

Drawbridge Amplifies 2021 Success with Senior Strategic Hires

Retrieved on: 
Monday, September 13, 2021
Security, Professional Services, Technology, Software, Human Resources, Financial technology, Managed services, Secureworks, Alternative investment, Goldman Sachs, GRC, Cane, Board, Member of the Scottish Parliament, Technology, Private equity, Menkes, Director, Software, Risk, Credit Suisse, Industry, COO, Morgan Stanley, Solution, Growth, Business development, Senior, Head, Compliance, Security Service, Vista Equity Partners, Service provider, Management, Risk management

2021 has been a breakthrough year for Drawbridge.

Key Points: 
  • 2021 has been a breakthrough year for Drawbridge.
  • To support its continued global growth, Drawbridge has added key strategic hires across critical areas of the business.
  • Prior to Drawbridge, Murphy served as Senior Vice President at BTIG.
  • Adam Menkes, Global Head of Operations, brings over twenty years of consulting experience in the Alternative Investment Industry to Drawbridge.

theScore Selects Toronto’s Waterfront Innovation Centre as Site for New, Expansive Headquarters

Retrieved on: 
Thursday, August 19, 2021
Entertainment, Sports, Other Sports, Commercial Building & Real Estate, Construction & Property, Casino, Gaming, Hive, Sun Life Financial, Menkes, Family, Empress Walk, Partnership, Exchange, Toronto Stock Exchange, Ecosystem, The Exchange, U.S. Securities and Exchange Commission, Engineering, AbemaTV, Sweeny&Co Architects Inc., Environment, Waterfront, CEO, Greater Toronto Area, Nasdaq, Menkes Developments, Technology, Trade, Telus Harbour, Sport, NASDAQ, Workforce, Company, Private Securities Litigation Reform Act, Economic development, Growth, Ownership, Hollywood Casino at Penn National Race Course, Acquisition, Unemployment, The Hive, National Caotun Commercial & Industrial Vocational Senior High School, Multimedia, Score Media and Gaming Inc., News, TSX, COVID-19, Risk management, Score Media and Gaming, Menkes, SCORE MEDIA AND GAMING, MENKES

View the full release here: https://www.businesswire.com/news/home/20210819005523/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20210819005523/en/
    theScores future headquarters at the Waterfront Innovation Centre, a cutting-edge complex on Torontos Sugar Beach.
  • The decision made by theScore to lease space at Torontos Waterfront Innovation Centre is not only a testament to the continued growth of our technology and innovation sector, but it will act as another confidence boost as we move forward in our pandemic recovery.
  • With theScore looking to expand and grow their business in Canada, we believe the Waterfront Innovation Centre will set them up for success through an environment that fosters collaboration by providing superior technology and amenities.
  • The Waterfront Innovation Centre, co-owned by Menkes and BentallGreenOak, on behalf of Sun Life Assurance Company of Canada, was developed in partnership with Waterfront Toronto, neighbours Sugar Beach on Toronto's eastern waterfront.